reSee.it Podcast Summary
Huberman and Dr. Sergu Pasca discuss autism, schizophrenia, and human brain development, tracing development from pregnancy through childhood and into the third decade of life. Pasca explains that autism is a spectrum with a strong genetic component and no universal biomarker, and notes rising prevalence—nearly 3% of the population—fueling searches for precise causes and targeted therapies.
Pasca describes organoids and assemblids, three-dimensional human brain circuits grown from stem cells in a dish, allowing direct study of neurodevelopment and psychiatric disease without first risking invasive brain tissue. Induced pluripotent stem cells via Yamanaka factors unlock patient-specific neurons; organoids recapitulate developmental timing, enable modeling of Timothy syndrome and other genetic forms, and support preclinical testing and potential cures.
Timothy syndrome is discussed as a diagnostic-physiologic model: patient-derived neurons show altered calcium dynamics; longer calcium influx and impaired extrusion. The team demonstrates that 3D organoids, transplanted into neonatal rat cortex, mature more fully than dish cultures, forming integrated networks with host vasculature and microglia, revealing phenotypes invisible in vitro and informing gene-therapy strategies.
Assemblies extend from simple two-neuron circuits to four-part, somatosensory pathways: cortex-to-spinal cord-to-thalamus-to-cortex, enabling spontaneous activity, functional testing of analgesics, and exploration of disease states such as epilepsy and autism-related circuitry. The researchers transplant organoid components into animals to study integration and response to sensory input, timing, and potential therapeutics, while emphasizing ethical considerations and nomenclature.
Looking ahead, Pasca discusses gene therapy, CRISPR, and delivery challenges in the brain, the value of patient-specific models for trial design, and dystonia and 22q11.2 deletion as models for broader neurological disease. He reflects on the ethical framework for organoid research, the self-correcting nature of science, and the goal of translating discoveries into safe, effective therapies for severe neurodevelopmental disorders.